Aamir Mahmood
President & CEO

Good morning, and welcome to the Q1 2026 earnings call from Acarix. I appreciate everybody joining this morning. And before we kick off, it's important for us to all kind of understand and realize that the world is in a very dynamic shift as we speak. The geopolitical tension, most prominently in the Middle East markets right now are ongoing, and we don't see an end in sight. However, what I want to rest assure is all operations from Acarix standpoint are fully functional. While we do have a lot of entry and focus within the MENA region, nothing has come to a stop. So things are moving along slower than expected. However, given the rhetoric and the challenges we face across the board globally, I think that everybody recognizes it, but it's important to make sure we address those situations as we continually press forward. Second, I'll apologize in advance, I have a mild cough due to my allergies, but nothing to be concerned about. So let's go ahead and move into the deck.

For all our new investors, thank you for joining. Just a quick update on who we are. This is -- we're Acarix. We have a CADScor System, and we're really trying to revolutionize early onset diagnostics in the cardiovascular range. We have a point-of-care device that is fairly quick, within 10 minutes, and can calculate a CAD-score for patients feeling low to moderate chest pain or shortness of breath. We can quickly and very easily identify those things using high-fidelity acoustics, listening into the arterial flow. And our negative predictive value is 96.2% in the United States and 97.2% in the European markets. We have over 15 years of R&D, over 45 patents, and we